Patents by Inventor Matthias Rueth

Matthias Rueth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES
    Publication number: 20230212277
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 23, 2022
    Publication date: July 6, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • HUMAN FCRN-BINDING MODIFIED ANTIBODIES AND METHODS OF USE
    Publication number: 20210395355
    Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.
    Type: Application
    Filed: July 12, 2021
    Publication date: December 23, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido Hartmann, Joerg Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • Human FcRn-binding modified antibodies and methods of use
    Patent number: 11091541
    Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: August 17, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Guido Hartmann, Joerg Thomas Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES
    Publication number: 20210095013
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 5, 2020
    Publication date: April 1, 2021
    Applicant: Roche Glycart AG
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
    Patent number: 10683345
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: June 16, 2020
    Assignee: Roche Glycart AG
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES
    Publication number: 20170260265
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 23, 2017
    Publication date: September 14, 2017
    Applicant: Roche Glycart AG
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
    Patent number: 9695233
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: July 4, 2017
    Assignee: ROCHE GLYCART AG
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • HUMAN FCRN-BINDING MODIFIED ANTIBODIES AND METHODS OF USE
    Publication number: 20160159894
    Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.
    Type: Application
    Filed: October 29, 2015
    Publication date: June 9, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Guido Hartmann, Joerg Thomas Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • FCRN-BINDING ABOLISHED ANTI-IGF-1R ANTIBODIES AND THEIR USE IN THE TREATMENT OF VASCULAR EYE DISEASES
    Publication number: 20160151487
    Abstract: The invention provides anti-IGF-1R antibodies with abolished FcRn-binding and methods of using the same for the treatment of vascular eye diseases.
    Type: Application
    Filed: October 29, 2015
    Publication date: June 2, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Guido Hartmann, Joerg Thomas Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function
    Publication number: 20140051834
    Abstract: Herein is reported an Fc-region fusion polypeptide or Fc-region conjugate comprising one to four incretin receptor ligand polypeptides and a variant human Fc-region with a mutation of the amino acid residue at position 329 and at least one further mutation of at least one amino acid selected from the group comprising amino acid residues at position 228, 233, 234, 235, 236, 237, 297, 318, 320, 322 and 331 to a different residue, wherein the residues in the Fc-region are numbered according to the EU index of Kabat and its use as a medicament.
    Type: Application
    Filed: June 18, 2013
    Publication date: February 20, 2014
    Applicants: Hoffmann-La Roche, Inc., Indiana University Research and Technology Corporation
    Inventors: Eike HOFFMAN, Erhard KOPETZKI, Matthias RUETH, Georg TIEFENTHALER, Richard D. DiMARCHI
  • Bispecific Anti-VEGF/Anti-ANG-2 Antibodies and their use in the Treatment of Ocular Vascular Diseases
    Publication number: 20140017244
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: July 11, 2013
    Publication date: January 16, 2014
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • Pentacyclic kinase inhibitors
    Patent number: 7749994
    Abstract: The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein A, X, Y, Z, Ra, Rb, Rc, R1, R2, R3 and m are defined herein.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: July 6, 2010
    Assignees: Genentech, Inc., Hoffman-LaRoche, Inc. (US Only), F. Hoffman-LaRoche, AG (EX-US)
    Inventors: Thomas E. Rawson, Brian Safina, Jennafer Dotson, Aihe Zhou, Ignacio Aliagas-Martin, Jason Halladay, Jun Liang, Matthias Rueth, Bing-Yan Zhu, Frederick Brookfield, Michael Prime, Birong Zhang, Jun M. Li
  • SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS
    Publication number: 20090291968
    Abstract: Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: March 21, 2007
    Publication date: November 26, 2009
    Inventors: Guy Georges, Bernhard Goller, Anja Limberg, Petra Rueger, Matthias Rueth, Christine Schuell, Mark Stahl
  • PHTHALAZINONE PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS
    Publication number: 20090221599
    Abstract: Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: March 16, 2007
    Publication date: September 3, 2009
    Inventors: Edward Boyd, Frederick Brookfield, Steve Courtney, Guy Georges, Bernhard Goller, Anja Limberg, Michael Prime, Petra Rueger, Matthias Rueth
  • Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents
    Publication number: 20090143375
    Abstract: Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: December 13, 2006
    Publication date: June 4, 2009
    Applicant: F. HOFFMANN-LA ROCHE AG
    Inventors: Guy Georges, Bernhard Goller, Hans-Willi Krell, Anja Limberg, Ulrike Reiff, Petra Rueger, Matthias Rueth, Christine Schuell, Mark Stahl
  • Methods of inhibiting BTK and SYK protein kinases
    Patent number: 7501410
    Abstract: Methods of inhibiting a tyrosine kinase wherein said tyrosine kinase is BTK or SYK comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to formula I are disclosed. The compounds are useful for treating auto-immune and inflammatory diseases.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: March 10, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: David Michael Goldstein, Matthias Rueth
  • Aminopyrazole derivatives
    Patent number: 7462639
    Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: December 9, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Guy Georges, Bernhard Goller, Klaus-Peter Kuenkele, Aude Lemarchand, Anja Limberg, Ulrike Reiff, Petra Rueger, Matthias Rueth
  • Oxidized thioether derivatives
    Patent number: 7405231
    Abstract: The present invention provides the compounds of formula I their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: March 4, 2005
    Date of Patent: July 29, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Walter-Gunar Friebe, Thomas Friess, Lothar Kling, Matthias Rueth, Edgar Voss
  • Indole derivatives
    Patent number: 7342030
    Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: March 11, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Thomas Friess, Ulrike Reiff, Matthias Rueth, Edgar Voss
  • Tricycles, their manufacture and use as pharmaceutical agents
    Patent number: 7285569
    Abstract: The present invention relates to compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: October 23, 2007
    Assignee: Hoff Hoffmann-La Roche Inc.
    Inventors: Georges Guy, Bernhard Goller, Hans-Willi Krell, Klaus-Peter Kuenkele, Anja Limberg, Petra Rueger, Matthias Rueth